Success Metrics

Active Trials

4(50%)

Phase Distribution

Ph phase_1

38%

Ph phase_2

50%

Ph early_phase_1

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Early Phase 1First-in-human

1(12.5%)

Phase 1Safety & dosage

3(37.5%)

Phase 2Efficacy & side effects

4(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(6)

Other(2)

Detailed Status

Recruiting4

Not yet recruiting1

Suspended1

Enrolling by invitation1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (12.5%)

Phase 13 (37.5%)

Phase 24 (50.0%)

Trials by Status

not_yet_recruiting113%

recruiting450%

suspended113%

enrolling_by_invitation113%

unknown113%

Recent Activity

4 active trials

Showing 5 of 8

recruitingphase_1

Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors.

NCT07570563

recruitingphase_1

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

NCT05702853

recruitingphase_2

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

NCT06107673

enrolling_by_invitationearly_phase_1

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

NCT06499025

recruitingphase_1

PTCy and ATG for MSD and MUD Transplants

NCT06299462

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07570563Phase 1

Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors.

Recruiting

NCT05702853Phase 1

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Recruiting

NCT06107673Phase 2

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Recruiting

NCT06499025Early Phase 1

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

Enrolling By Invitation

NCT06299462Phase 1

PTCy and ATG for MSD and MUD Transplants

Recruiting

NCT05303727Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not Yet Recruiting

NCT02897050Phase 2

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Suspended

NCT04620772Phase 2

Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis

Unknown

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8